JOGC

Managing Menopause Chapter 4 Vasomotor Symptoms

        VMS affect 60% to 80% of women entering menopause.
        • Freeman E.W.
        • Sherif K.
        Prevalence of hot flushes and night sweats around the world: a systematic review.
        Hot flashes are common in the perimenopausal transition, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder.
        • Hahn P.M.
        • Wong J.
        • Reid R.L.
        Menopausal-like hot flashes reported in women of reproductive age.
        After menopause, it is important to be alert to atypical features or to a lack of response to effective therapy, which might indicate an alternative cause of the symptoms. The differential diagnosis includes hyperthyroidism, anxiety, panic attack, hypertension, emotional flushing, neurologic flushing, carcinoid, physical deconditioning, tumours, spinal cord injury, and reactions to food, drugs, and alcohol.
        • Mohyi D.
        • Tabassi K.
        • Simon J.
        Differential diagnosis of hot flashes.
        In menopausal women hot flashes are thought to result from a disturbance of the temperature-regulating mechanism in the hypothalamus that is due to low estrogen levels after prior estrogen priming.
        To read this article in full you will need to make a payment

        REFERENCES

          • Freeman E.W.
          • Sherif K.
          Prevalence of hot flushes and night sweats around the world: a systematic review.
          Climacteric. 2007; 10: 197-214
          • Hahn P.M.
          • Wong J.
          • Reid R.L.
          Menopausal-like hot flashes reported in women of reproductive age.
          Fertil Steril. 1998; 70: 913-918
          • Mohyi D.
          • Tabassi K.
          • Simon J.
          Differential diagnosis of hot flashes.
          Maturitas. 1997; 27: 203-214
          • Kronenberg F.
          Hot flashes: epidemiology and physiology.
          Ann N Y Acad Sci. 1990; 592: 52-86
          • Hunter M.
          • Rendall M.
          Biopsychosociocultural perspectives on menopause.
          Best Pract Res Clin Obstet Gynaecol. 2007; 21: 261-274
          • Whiteman M.K.
          • Staropoli C.A.
          • Lnagenberg P.W.
          • McCarter R.J.
          • Kjerulff K.H.
          • Flaws J.A.
          Smoking, body mass and hot flashes in midlife women.
          Obstet Gynecol. 2003; 101: 264-272
          • Utian W.H.
          Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review.
          Health Qual Life Outcomes. 2005; 3: 47
          • Archer D.F.
          • Sturdee D.W.
          • Baber R.
          • de Villiers T.J.
          • Pines A.
          • Freedman R.R.
          • et al.
          Menopausal hot flushes and night sweats: where are we now?.
          Climacteric. 2011; 14 (Epub 2011 Aug 18): 515-528
          • Freedman R.R.
          Hot flashes: behavioral treatments, mechanisms, and relation to sleep.
          Am J Med. 2005; 118: 124S-130S
          • Gold E.B.
          • Colvin A.
          • Avis N.
          • Bromberger J.
          • Greendale G.A.
          • Powell L.
          • et al.
          Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation.
          Am J Public Health. 2006; 96 (Epub 2006 May 30): 1226-1235
          • Maclennan A.H.
          • Broadbent J.L.
          • Lester S.
          • Moore V.
          Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.
          Cochrane Database Syst Rev. 2004; 4: CD002978
          • Schiff I.
          • Tulchinski D.
          • Cramer D.
          • Ryan K.J.
          Oral medroxyprogesterone in the treatment of postmenopausal symptoms.
          JAMA. 1980; 244: 1443-1445
          • Bullock J.L.
          • Massey F.M.
          • Gambrell R.D.
          Use of medroxypregesterone acetate to prevent menopausal symptoms.
          Obstet Gynecol. 1975; 46: 165-168
          • Prior J.C.
          • Nielsen J.D.
          • Hitchcock C.L.
          • Williams L.A.
          • Vigna Y.M.
          • Dean C.B.
          Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
          Clin Sci (Lond). 2007; 112: 517-525
          • Hitchcock C.L.
          • Prior J.C.
          Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women.
          Menopause. 2012; 19: 886-893
          • Pandya K.J.
          • Raubertas R.F.
          • Flynn P.J.
          • Hynes H.E.
          • Rosenbluth R.J.
          • Kirshner J.J.
          • et al.
          Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.
          Ann Intern Med. 2000; 132: 788-793
          • Goldberg R.M.
          • Loprinzi C.L.
          • O’Fallon J.R.
          • Veeder M.H.
          • Miser A.W.
          • Mailliard J.A.
          • et al.
          Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.
          J Clin Oncol. 1994; 12: 155-158
          • Rapkin A.J.
          Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment.
          Am J Obstet Gynecol. 2007; 196: 97-106
          • Speroff L.
          • Gass M.
          • Constantine G.
          • Olivier S.
          • Study 315 Investigators
          Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
          Obstet Gynecol. 2008; 111: 77-87
          • Reddy S.Y.
          • Warner H.
          • Guttuso Jr., T.
          • Messing S.
          • DiGrazio W.
          • Thornburg L.
          • et al.
          Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
          Obstet Gynecol. 2006; 108: 41-48
          • Loprinzi C.L.
          • Qin R.
          • Baclueva E.P.
          • Flynn K.A.
          • Rowland Jr., K.M.
          • Graham D.L.
          • et al.
          Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes.
          J Clin Oncol. 2010; 28 (Epub 2009 Nov 9): 641-647
          • Hall E.
          • Frey B.N.
          • Soares C.N.
          Non-hormonal treatment strategies for vasomotor symptoms: a critical review.
          Drugs. 2011; 71: 287-304
          • Nelson H.D.
          • Vesco K.K.
          • Haney E.
          • Fu R.
          • Nedrow A.
          • Miller J.
          • et al.
          Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.
          JAMA. 2006; 295: 2057-2071
          • Thacker H.L.
          Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women.
          J Womens Health. 2011; 20: 1007-1016
          • McIntyre R.S.
          • Konarski J.Z.
          • Grigoriadis S.
          • Fan N.C.
          • Mancini D.A.
          • Fulton K.A.
          • et al.
          Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship.
          CMAJ. 2005; 172: 57-59
          • Pachman D.R.
          • Morgenthaler T.I.
          • Loprizini C.L.
          Hot flashes and antidepressant agents: uneasy bedfellows.
          Menopause. 2012; 19: 839-842
          • Moret C.
          • Isaac M.
          • Briley M.
          Problems associated with long-term treatment with selective serotonin reuptake inhibitors.
          J Psychopharmacol. 2009; 23 (Epub 2008 Jul 17): 967-974
          • Pines A.
          • Sturdee D.W.
          • MacLennan A.H.
          Quality of life and the role of menopausal hormone therapy.
          Climacteric. 2012; 15: 213-216
          • Islam S.
          • Liu Q.
          • Chines A.
          • Helzner E.
          Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000–2005.
          Menopause. 2009; 16: 77-83
          • Karim R.
          • Dell R.M.
          • Greene D.F.
          Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization.
          Menopause. 2011; 18: 1172-1177
          • Butt D.A.
          • Lock M.
          • Lewis J.E.
          • Ross S.
          • Moineddin R.
          Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial.
          Menopause. 2008; 15: 310-318
          • Toulis K.A.
          • Tzellos T.
          • Kouvelas D.
          • Goulis D.G.
          Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis.
          Clin Ther. 2009; 31: 221-235
          • Reddy S.Y.
          • Warner H.
          • Guttuso Jr., T.
          • Messing S.
          • DiGrazio W.
          • Thornburg L.
          • et al.
          Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
          Obstet Gynecol. 2006; 108: 41-48
          • Loprinzi C.L.
          • Kugler J.W.
          • Barton D.L.
          • Dueck A.C.
          • Tschetter L.K.
          • Nelimark R.A.
          • et al.
          Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.
          J Clin Oncol. 2007; 25 (Epub 2006 Dec 4): 308-312
          • Brett K.M.
          • Keenan N.L.
          Complementary and alternative medicine use among midlife women for reasons including menopause in the United States: 2002.
          Menopause. 2007; 14: 300-307
          • Ang-Lee M.K.
          • Moss J.
          • Yuan C.S.
          Herbal medicines and perioperative care.
          JAMA. 2001; 286: 208-216
          • Mills E.
          • Wu P.
          • Johnston B.C.
          • Gallicano K.
          • Clarke M.
          • Guyatt G.
          Natural health product—drug interactions: a systematic review of clinical trials.
          Ther Drug Monit. 2005; 27: 549-5547
          • Tsai H.H.
          • Lin H.W.
          • Pickard A.S.
          • Tsai H.Y.
          • Mahady G.B.
          Evaluation of documented drug interactions and contraindications associated with herbs and dietary supplements: a systematic literature review.
          Int J Clin Pract. 2012; 66: 1056-1078
          • Singh S.R.
          • Levine M.A.
          Potential interactions between pharmaceuticals and natural health products in Canada.
          J Clin Pharmacol. 2007; 47: 249-258
          • Moss K.
          • Boon H.
          • Ballantyne P.
          • Kachan N.
          New Canadian natural health product regulations: a qualitative study of how CAM practitioners perceive they will be impacted.
          BMC Complement Altern Med. 2006; 6 (Epub 2006 May 10): 18
          • Speroff L.
          Alternative therapies for postmenopausal women.
          Int J Fertil Womens Med. 2005; 50: 101-104
          • Kronenberg F.
          • Fugh-Berman A.
          Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials.
          Ann Intern Med. 2002; 137: 805-813
          • Huntley A.L.
          • Ernst E.
          A systematic review of herbal medicinal products for the treatment of menopausal symptoms.
          Menopause. 2003; 10: 465-476
          • Nedrow A.
          • Miller J.
          • Walker M.
          • Nygren P.
          • Huffman L.H.
          • Nelson H.D.
          Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review.
          Arch Intern Med. 2006; 166: 1453-1465
          • Nelson H.D.
          • Vesco K.K.
          • Haney E.
          • Fu R.
          • Nedrow A.
          • Miller J.
          • et al.
          Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis.
          JAMA. 2006; 295: 2057-2071
          • Newton K.M.
          • Reed S.D.
          • LaCroix A.Z.
          • Grothaus L.C.
          • Ehrlich K.
          • Guiltinan J.
          Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial.
          Ann Intern Med. 2006; 145: 869-879
          • Stuenkel C.A.
          • Gass M.L.S.
          • Manson J.A.E.
          • Lobo R.A.
          • Pal L.
          • Rebar R.W.
          • et al.
          A decade after the Women’s Health Initiative—the experts do agree.
          Menopause. 2012; 19: 846-847
          • Mirkin S.
          • Pickar J.H.
          Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination.
          Int J Womens Health. 2013; 5 (Epub 2013 Aug 7): 465-475

        Linked Article

        • ERRATA
          Journal of Obstetrics and Gynaecology Canada Vol. 37Issue 6
          • In Brief
            Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, et al; SOGC Menopause and Osteoporosis Working Group. Managing menopause. SOGC Clinical Practice Guideline No. 311, September 2014. J Obstet Gynaecol Can 2014;36(9 Suppl 2):S33-S80.
          • Full-Text
          • PDF